MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares barely moved at the open Thursday. The Miami-based company, a clinical-stage pharmaceutical concern developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical pharmacology data on Mira-55, the Company's cannabinoid analog in development for chronic inflammatory pain. Mira-55 is designed to act on the same cannabinoid receptors as compounds found in cannabis, including THC.
A central pharmacological question for the program is whether Mira-55 can deliver therapeutic activity through that receptor system without carrying THC's known liabilities, including psychoactivity and central nervous system side effects. This new study addresses that question directly.
Using a standard test researchers rely on to characterize THC-like compounds, Mira-55 showed a pharmacological profile that sets it apart from THC, including a meaningful anxiolytic effect that THC does not produce.
These findings build on data MIRA reported in March 2026, which showed Mira-55 did not produce THC-like side effects and demonstrated anxiety-reducing activity in animal testing, in contrast to rimonabant, a drug that blocks the same receptor THC acts on.
Together, the two studies form a consistent picture: Mira-55 engages the cannabinoid system differently than THC does, and that difference shows up at both the behavioral and mechanistic levels.
MIRA shares dipped 0.005 cents to 91 cents.
